The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia
- PMID: 31883804
- DOI: 10.1016/j.blre.2019.100650
The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia
Abstract
Patients with acute myeloid leukemia (AML) who achieve morphologic remission in the bone marrow after initial treatment often continue to harbor residual leukemic cells that can give rise to disease relapse. Achievement of a deeper remission has been associated with a reduced risk of relapse and improved event-free and overall survival in several studies. However, standardization of diagnostic techniques, sample acquisition and test timing are needed before minimal, also known as measurable, residual disease (MRD) quantification can be used to guide treatment decision making. Furthermore, clinical trial evidence that preemptive intervention at MRD level can alter the natural history of AML is required. Herein, we outline the current landscape of MRD assessment in AML, summarize the available evidence and challenges, and highlight the potential for MRD status to serve as a surrogate endpoint for hard clinical outcomes and as an approvable endpoint in clinical trials for regulatory purposes.
Keywords: Acute myeloid leukemia; Immune checkpoint; MRD; Minimal residual disease; Next generation sequencing.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest A.M.Z. received research funding (institutional) from Celgene, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, and Epizyme. A.M.Z received travel support for meetings from Pfizer, Novartis, and Trovagene. None of these relationships were related to the development of this manuscript. The other authors have no relevant conflicts of interest to declare.
Similar articles
-
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.J Hematol Oncol. 2021 Sep 3;14(1):137. doi: 10.1186/s13045-021-01148-5. J Hematol Oncol. 2021. PMID: 34479626 Free PMC article. Review.
-
A mind map for managing minimal residual disease in acute myeloid leukemia.Clin Adv Hematol Oncol. 2017 Nov;15(11):859-867. Clin Adv Hematol Oncol. 2017. PMID: 29200419 Review.
-
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492. Int J Mol Sci. 2018. PMID: 30404199 Free PMC article. Review.
-
Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.Surg Pathol Clin. 2019 Sep;12(3):671-686. doi: 10.1016/j.path.2019.03.009. Epub 2019 May 18. Surg Pathol Clin. 2019. PMID: 31352980 Review.
-
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6. Blood. 2018. PMID: 30190321 Free PMC article.
Cited by
-
Targeting PRAME for acute myeloid leukemia therapy.Front Immunol. 2024 Mar 26;15:1378277. doi: 10.3389/fimmu.2024.1378277. eCollection 2024. Front Immunol. 2024. PMID: 38596687 Free PMC article. Review.
-
Aging-related genes related to the prognosis and the immune microenvironment of acute myeloid leukemia.Clin Transl Oncol. 2023 Oct;25(10):2991-3005. doi: 10.1007/s12094-023-03168-8. Epub 2023 Apr 17. Clin Transl Oncol. 2023. PMID: 37067728
-
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.Leuk Res. 2022 Dec;123:106971. doi: 10.1016/j.leukres.2022.106971. Epub 2022 Oct 21. Leuk Res. 2022. PMID: 36332294 Free PMC article. Clinical Trial.
-
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.Am J Hematol. 2023 Jan;98(1):79-89. doi: 10.1002/ajh.26757. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36251406 Free PMC article.
-
Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.Front Immunol. 2022 Sep 29;13:999298. doi: 10.3389/fimmu.2022.999298. eCollection 2022. Front Immunol. 2022. PMID: 36248870 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical